Dosage ; Elderly 0.25mg BD or TID.
Other adult 0.25mg-0.5mg TID. (max 3mg daily)
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Adco-Alzam | Adcock ingram E.A. | Adcock ingram E.A. | 1mg | 30 | Tablet | per tablet | KES 750 |
| Alzolam | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 0.25mg | 100 | Tablet | per tablet | KES 2,000.00 |
| Alzolam | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 0.5mg | 100 | Tablet | per tablet | KES 2,800.00 |
| Atrest | Centaur Pharmaceuticals Ltd. | Sai Pharmaceuticals Ltd. | 0.25mg | 30 | Tablet | per tablet | KES 210.00 |
| Atrest | Centaur Pharmaceuticals Ltd. | Sai Pharmaceuticals Ltd. | 0.5mg | 30 | Tablet | per tablet | KES 383.00 |
| Xanax | Pfizer Global Pharmaceuticals | Surgipharm Ltd | 0.25mg | 30 | Tablet | per tablet | KES 465.56 |
| Xanax | Pfizer Global Pharmaceuticals | Surgipharm Ltd | 0.5mg | 30 | Tablet | per tablet | KES 871.00 |
| Xanax | Pfizer Global Pharmaceuticals | Surgipharm Ltd | 0.5mg | 100 | Tablet | per tablet | KES 2,144.00 |
| Poex | Biopharma Laboratories Ltd. | Maxim Pharmaceuticals Ltd | 0.25mg | 10 | Tablet | per tablet | KES 900.00 |
| Poex | Biopharma Laboratories Ltd. | Maxim Pharmaceuticals Ltd | 0.50mg | 10 | Tablet | per tablet | KES 1,800.00 |
Alprazolam more info |
|
|---|---|
| Mode Of Action | Potentiation of the effect of gamma-amino butyrate (GABA). Example: diazepam, |
| Drug Indication | Anxiety, associated with depression (short term use). |
| Dosage | Elderly 0.25mg BD or TID. Other adult 0.25mg-0.5mg TID. (max 3mg daily) |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Hypnotics, sedatives & tranquilizers |
| Alprazolam | |
|---|---|
| Mode Of Action | Potentiation of the effect of gamma-amino butyrate (GABA). Example: diazepam, |
| Drug Indication | Anxiety, associated with depression (short term use). |
| Dosage | Elderly 0.25mg BD or TID. Other adult 0.25mg-0.5mg TID. (max 3mg daily) |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Hypnotics, sedatives & tranquilizers
Specific Dosage Use Treatment of anxiety disorder (GAD); panic disorder, with or without agoraphobia; anxiety associated with depression Dosing: Adult Note: Treatment >4 months should be re-evaluated to determine the patient's continued need for the drug Anxiety: Oral: Immediate release: Effective doses are 0.5-4 mg/day in divided doses; the manufacturer recommends starting at 0.25-0.5 mg 3 times/day; titrate dose upward; usual maximum: 4 mg/day. Patients requiring doses >4 mg/day should be increased cautiously. Periodic reassessment and consideration of dosage reduction is recommended. Anxiety associated with depression: Oral: Immediate release: Average dose required: 2.5-3 mg/day in divided doses Ethanol withdrawal (unlabeled use): Oral: Immediate release: Usual dose: 2-2.5 mg/day in divided doses Panic disorder: Oral: Immediate release: Initial: 0.5 mg 3 times/day; dose may be increased every 3-4 days in increments ≤1 mg/day. Mean effective dosage: 5-6 mg/day; many patients obtain relief at 2 mg/day, as much as 10 mg/day may be required Extended release: 0.5-1 mg once daily; may increase dose every 3-4 days in increments ≤1 mg/day (range: 3-6 mg/day) Switching from immediate release to extended release: Patients may be switched to extended release tablets by taking the total daily dose of the immediate release tablets and giving it once daily using the extended release preparation. Preoperative sedation: Oral: 0.5 mg in evening at bedtime and 0.5 mg 1 hour before procedure Dose reduction: Abrupt discontinuation should be avoided. Daily dose may be decreased by 0.5 mg every 3 days, however, some patients may require a slower reduction. If withdrawal symptoms occur, resume previous dose and discontinue on a less rapid schedule. Dosing: Pediatric (For additional information see "Alprazolam: Pediatric drug information") Anxiety (unlabeled use): Oral: Immediate release: Initial: 0.005 mg/kg/dose or 0.125 mg/dose 3 times/day; increase in increments of 0.125-0.25 mg, up to a maximum of 0.02 mg/kg/dose or 0.06 mg/kg/day (0.375-3 mg/day). See "Dose Reduction" comment in adult dosing. Note: Treatment >4 months should be re-evaluated to determine the patient's continued need for the drug. Dosing: Geriatric Initial: 0.125-0.25 mg twice daily; increase by 0.125 mg/day as needed. The smallest effective dose should be used. Immediate release: Initial 0.25 mg 2-3 times/day Extended release: Initial: 0.5 mg once daily Dosing: Renal Impairment No guidelines for adjustment; use caution. Dosing: Hepatic Impairment Oral: Reduce dose by 50% to 60% or avoid in cirrhosis |